Pancreatic Cancer Research

ResearcherUniversity of OxfordActive in the last 2 years

Emmanouil Fokas Fokas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1601-6165; OpenAlex author ID A5028206592. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: none · 2015: 2 papers · 2016: 7 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 16

  1. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. Co-author DOI 10.1159/000538171↗
  2. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-16-2833↗
  3. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. Last author DOI 10.15252/emmm.201606674↗
  4. [The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer]. First author DOI 10.1007/s00066-016-1058-9↗
  5. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. First author DOI 10.1016/j.radonc.2016.03.021↗
  6. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Co-author DOI 10.1016/j.radonc.2016.07.002↗
  7. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Co-author DOI 10.1186/s12885-016-2765-4↗
  8. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.10038↗
  9. Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.12022↗
  10. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.6770↗
  11. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Co-author DOI 10.1016/j.bbcan.2014.12.001↗
  12. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP tr… Co-author DOI 10.1016/j.radonc.2015.08.026↗
  13. Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Co-author DOI 10.1007/s00066-013-0332-3↗
  14. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Co-author DOI 10.1016/j.radonc.2013.04.010↗
  15. Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advan… Co-author DOI 10.3109/0284186x.2013.813072↗
  16. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. First author DOI 10.4161/cbt.21093↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ruth J. Muschel · 7 shared papers, 2012–2017 · strength 0.38
  2. Thomas Baptist Brunner · 6 shared papers, 2012–2016 · strength 0.33
  3. Somnath Mukherjee · 6 shared papers, 2015–2016 · strength 0.32
  4. Zenobia D’Costa · 5 shared papers, 2016–2017 · strength 0.29
  5. Abul Kalam Azad · 4 shared papers, 2016–2017 · strength 0.23
  6. Angela Diana · 3 shared papers, 2016–2017 · strength 0.17
  7. Lai Mun Wang · 3 shared papers, 2016 · strength 0.16
  8. Eric E. O’Neill · 3 shared papers, 2016–2017 · strength 0.16
  9. Ralf‐Dieter Hofheinz · 1 shared paper, 2024 · strength 0.13
  10. Andrea Tannapfel · 1 shared paper, 2024 · strength 0.13
  11. Céline Lugnier · 1 shared paper, 2024 · strength 0.13
  12. Jan Schildmann · 1 shared paper, 2024 · strength 0.13
  13. Jochen M. Schmitt · 1 shared paper, 2024 · strength 0.13
  14. Bernhard Josef Wormann · 1 shared paper, 2024 · strength 0.13
  15. Uwe Pelzer · 1 shared paper, 2024 · strength 0.13
  16. Anke Reinacher‐Schick · 1 shared paper, 2024 · strength 0.13
  17. Samantha Warren · 3 shared papers, 2013 · strength 0.13
  18. Keaton Ian Jones · 2 shared papers, 2017 · strength 0.12
  19. Owen James Sansom · 2 shared papers, 2017 · strength 0.12
  20. Ross Allen Abrams · 2 shared papers, 2015–2016 · strength 0.11
  21. Chris N Hurt · 2 shared papers, 2015–2016 · strength 0.11
  22. M. Hawkins · 2 shared papers, 2016 · strength 0.10
  23. Mike Partridge · 2 shared papers, 2013–2016 · strength 0.09
  24. Eric O’Neill · 1 shared paper, 2015 · strength 0.06
  25. Alex Nicolas Gordon-Weeks · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.